Alcresta Presents Product Data for Cystic Fibrosis at 29th Annual North American Cystic Fibrosis Conference (#NACFC)

Daniela Semedo, PhD avatar

by Daniela Semedo, PhD |

Share this article:

Share article via email
P. aeruginosa lung infection in cystic fibrosis

Alcresta, a company dedicated to developing and commercializing novel enzyme-based products that address the challenges faced by patients with gastrointestinal disorders and rare diseases such as cystic fibrosis recently presented at the 29th Annual North American Cystic Fibrosis Conference (NACFC) new clinical results reporting on its product and technology. The conference is taking place in Phoenix, Arizona from the 8th to the 10th of October, and serves as a collaborative forum to advance research for the treatment and cure of cystic fibrosis (CF).

Alcresta uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases.

The results that were presented during the conference were as follows:

  • Novel Immobilized iLipase Device (EFIC) Enhances the Nutritional Benefits of Enteral Feeding and Provides Greater Flexibility for Shorter Duration Feedings and Reduced Volumes” , as study that highlighted the use of EFIC in an animal model. The results were presented by senior director Greta Loring, new product planning, this past Thursday (Oct. 8th) between 10am and 11:45 a.m. during a session in Room 120D known as “Nutrition Research”. The data abstract was also available in a poster (#557) on Thursday (Oct 8th), between 11:50 a.m. and 1:50 p.m., and will be again available this Saturday (Oct.10th), between 7:30 a.m. and 8:45 a.m.
  • In-Line Digestive Enzyme Cartridge (EFIC), as a Part of Enteral Feeding, Facilitates Effective Fat Absorption and Increases Omega 3 Plasma Levels in Pig Model of Exocrine Pancreatic Insufficiency (EPI)” will present data following 12 days of enteral tube feeding using EFIC in EPI porcine model. These results were presented by senior director Danica Grujic, pharmacology this Friday (Oct. 9th), between 2:00 p.m. and 3:45 p.m. during a session entitled “Gastroenterology/Liver/Pancreas” taking place at Room 120D. The results abstract were available in a poster (#563) this Thursday (Oct. 8th), and will be again available this Saturday (Oct. 10th), between 7:30 a.m. and 8:45 a.m.
  • “Long Term Positive Effects of G-tube Feeding with an In-line EFIC on the Tissue Levels of DHA and EPA in Pig Model of Exocrine Pancreatic Insufficiency (EPI)” underscored the utilization of this digestive enzyme cartridge in patients who are being fed by enteral tube. The poster was available this past Thursday (Oct. 8th), and were again available today (Oct. 9), between 7:30 a.m. to 8:45 a.m.

While the impact that cystic fibrosis has on the lungs is a primary focus in research and development, the effect that CF has on digestion and nutrient absorption is also a major factor in treating the disease. Development efforts from companies such as Alcresta are helping to advance new therapies that can address these health issues in those with CF, improving patient outcomes.